Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) Invested Capital (2022 - 2026)

Kura Oncology has reported Invested Capital over the past 5 years, most recently at $107.9 million for Q1 2026.

  • Quarterly Invested Capital fell 70.55% to $107.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $107.9 million through Mar 2026, down 70.55% year-over-year, with the annual reading at $183.8 million for FY2025, 55.84% down from the prior year.
  • Invested Capital was $107.9 million for Q1 2026 at Kura Oncology, down from $183.8 million in the prior quarter.
  • Over five years, Invested Capital peaked at $505.1 million in Q1 2024 and troughed at $107.9 million in Q1 2026.
  • The 5-year median for Invested Capital is $406.8 million (2023), against an average of $366.4 million.
  • Year-over-year, Invested Capital grew 27.81% in 2024 and then tumbled 70.55% in 2026.
  • A 5-year view of Invested Capital shows it stood at $420.3 million in 2022, then decreased by 5.47% to $397.3 million in 2023, then rose by 4.78% to $416.2 million in 2024, then plummeted by 55.84% to $183.8 million in 2025, then plummeted by 41.32% to $107.9 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Invested Capital are $107.9 million (Q1 2026), $183.8 million (Q4 2025), and $246.9 million (Q3 2025).